Biotech Startups in Autoimmune Disease Field, Part 1
Biotech companies are developing potential novel therapeutics to treat various autoimmune diseases like multiple sclerosis, diabetes, allergies, inflammatory bowel disease, lupus, and others. Further details about the clinical studies for biotech companies listed in rows 2-14 have been provided in the attached spreadsheet.
Summary of findings
- Arch VeturePartners, Lyell, Milky Way Ventures, and 8VC have invested a total of $40 million in Sonoma Bio.
- Sandy Macrae, Stéphane Boissel, Adrian Woolfson, Bettina Cockroft, Jason Fontenot, and Roger Kornberg are the key founders of TxCell acquired by Sangamo.
- Sangamo has generated a total capital of $93.2 million.
- Some clinical trials of Sangamo are Phase 1&2 Fabry Disease (ST-920), Phase 1&2 Hemophilia A (SB-525), Phase 1&2 Beta Thalassemia (ST-400), Phase 1&2 MPS II (SB-913), and Sickle Cell Disease (BIVV003).
- Allogenes clinical trials includes "Phase 1 Study, evaluating the safety, efficacy, and cellular kinetics/pharmacodynamics of ALLO-501 in patients with relapsed/refractory large B-Cell lymphoma or follicular lymphoma" and "Phase 1 clinical trial of UCART19 licensed from Servier for relapsed/refractory acute lymphoblastic leukemia (ALL)"
To provide the requested details for the biotech companies, we scoured through their websites, press releases, media publications, industry reports, and company databases like Crunchbase, Pitchbook, and others. However, we were unable to provide preclinical works and clinical trials of Sonoma Biotherapeutics and Allero Therapeutics, and total funding capital of BTB Pharma. This is because these companies are yet to reach the preclinical and clinical phases of their research. As for BTB Pharma's funding total, we searched its website, press releases, media publications and company databases such as Crunchbase and Zoominfo. However, these strategies were futile. We only found information about the company's investors and revenue among others but nothing about its funding amounts. It was also noted that many European companies did not initiate clinical trials in the United States. Hence, we were unable to identify any ongoing or past clinical studies from the official US clinical trials' database. Consequently, we entered N/A in columns G and H. We have provided the requested details about the biotech companies in the attached spreadsheet.